{
  "ticker": "LLY",
  "analysis_asof": "2026-04-15T02:06:59.866670+09:00",
  "market_data_asof": "2026-04-14",
  "level_basis": "daily_close",
  "thesis_state": "constructive",
  "primary_setup": "watch_only",
  "portfolio_stance": "BULLISH",
  "entry_action_base": "WAIT",
  "setup_quality": "DEVELOPING",
  "confidence": 0.66,
  "action_if_triggered": "NONE",
  "starter_fraction_of_target": null,
  "breakout_level": null,
  "breakout_confirmation": "close_above",
  "pullback_buy_zone": null,
  "invalid_if_close_below": null,
  "invalid_if_intraday_below": null,
  "min_relative_volume": 1.0,
  "session_vwap_preference": "indifferent",
  "event_guard": {
    "earnings_date": null,
    "block_new_position_within_days": 0,
    "allow_add_only_after_event": false,
    "requires_post_event_rerun": false
  },
  "reason_codes": [
    "trigger:lly가_955_위에서_종가를_형성하고_상대강도지수_50_상회와_거래량_확대가_동반되면_소규모_시작_진입을_",
    "trigger:981-985의_50일_단순이동평균_저항을_돌파한_뒤_유지하면_추가_매수_또는_비중확대_검토로_상향한다.",
    "trigger:900-901_재시험에서_매도_거래량이_줄고_가격이_빠르게_안정되면_위험이_정의된_시작_진입_후보로_유지한다",
    "trigger:925_또는_거래량가중이동평균_아래_종가와_이동평균_수렴·확산_막대_약화가_함께_나타나면_반등_실패_경고로_",
    "trigger:900-901_아래_반복_종가_또는_878.24_이탈은_상승_관점을_중립_또는_방어적_관점으로_낮추는_신호다",
    "trigger:foundayo의_신규_처방,_보험_적용,_공급,_마진,_경영진_가이던스_자료를_확인한다."
  ],
  "notes": [
    "catalyst:foundayo의_승인과_$149/month_미국_출시가_경구_비만_치료_수요를_확대할_수_있다.",
    "catalyst:2025년_분기_매출이_12.7b에서_15.6b,_17.6b,_19.3b_usd로_증가했고_4분기_영업이익이",
    "catalyst:선행_주가수익비율_약_22.3은_후행_주가수익비율_약_40.7보다_낮아,_수요와_생산능력_확대가_실행되면_이",
    "catalyst:centessa_및_crossbridge_bio_인수와_jaypirca_3상_긍정_자료가_비만_치료제_외_성",
    "catalyst:s&p_500_회복과_nasdaq_100의_10거래일_상승은_고품질_성장주에_우호적인_위험_선호_환경을_제공"
  ]
}